iRhythm Technologies (IRTC) insider plans $450,000 share sale via Morgan Stanley
Rhea-AI Filing Summary
iRhythm Technologies, Inc. (NASDAQ: IRTC) – Form 144 filing overview
On the latest Form 144 notice, insider Daniel Wilson has disclosed a proposed sale of 3,000 common shares of iRhythm Technologies. The sale will be executed through Morgan Stanley Smith Barney LLC on or about 23 June 2025. Based on the filing’s stated price, the transaction is valued at approximately $450,000.
iRhythm reports 31,925,267 shares outstanding; the proposed sale therefore equals roughly 0.009 % of the company’s issued shares. The shares being sold were originally acquired via company equity awards: 1,063 performance shares (27 Feb 2023), 970 restricted shares (1 Mar 2023) and 967 performance shares (27 Feb 2024).
The filing also lists insider sales during the previous three months: on 2 May 2025, Wilson sold 333 and 1,667 common shares for total gross proceeds of $250,000. The Form 144 certification states that the seller affirms no knowledge of undisclosed material adverse information at the time of filing.
Because the notice covers a relatively small portion of total shares outstanding and does not introduce new corporate information, the immediate market impact is expected to be limited; nevertheless, investors often track insider activity for signalling purposes.
Positive
- Sale volume is only about 0.009 % of outstanding shares, indicating minimal potential impact on share supply.
Negative
- Insider Daniel Wilson filed to sell 3,000 shares worth $450,000, following a 2,000-share sale earlier in the quarter.
Insights
TL;DR – Small insider sale (3,000 shares) worth $450k; minimal dilution, neutral information value.
The Form 144 reveals that Daniel Wilson plans to divest 3,000 iRhythm shares, following a 2,000-share sale in May 2025. With nearly 32 million shares outstanding, the upcoming transaction represents less than 0.01 % of float, suggesting negligible supply pressure. No price, earnings or operational data are included, and the filing affirms absence of undisclosed negative information. Insider activity merits monitoring, but the scale and context signal a largely neutral event for valuation.
TL;DR – Routine equity award liquidation; governance implications limited.
Wilson’s planned sale involves shares obtained from performance and restricted stock grants, typical for executive compensation. The Form 144 follows compliance requirements, lists broker details, and references Rule 10b5-1 protections. Prior sales were properly disclosed. Given the modest volume and adherence to reporting rules, the filing does not raise governance red flags, although continued insider selling could attract scrutiny if the pace accelerates.
FAQ
When is the approximate sale date for the insider transaction?
Were there recent insider sales prior to this notice?